pertuzumab biosimilar
/ Mabscale
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
August 16, 2024
Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man
(clinicaltrials.gov)
- P1 | N=114 | Active, not recruiting | Sponsor: Mabscale, LLC | Trial completion date: Jun 2024 ➔ Sep 2024
Trial completion date
February 28, 2024
Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man
(clinicaltrials.gov)
- P1 | N=114 | Active, not recruiting | Sponsor: Mabscale, LLC | Recruiting ➔ Active, not recruiting
Enrollment closed
August 22, 2023
Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man
(clinicaltrials.gov)
- P1 | N=114 | Recruiting | Sponsor: Mabscale, LLC | Not yet recruiting ➔ Recruiting
Enrollment open
April 24, 2023
Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man
(clinicaltrials.gov)
- P1 | N=114 | Not yet recruiting | Sponsor: Mabscale, LLC
New P1 trial
1 to 4
Of
4
Go to page
1